



Ian Churcher
MA, DPhil
Founder & CEO, Janus
Drug Discovery
Consulting Ltd



Why work with Janus DD Consulting?

With a track record of delivery from over 25 years in biotech and pharma Janus can help investors and management teams across strategic and operational scientific aspects at all phases from Newco creation & R&D team build-out through to delivery of pre-clinical milestones to underpin funding rounds and collaboration/M&A deal signing.

Extensive pharma & biotech C-suite experience in pre-clinical drug discovery using range of small molecule approaches in multiple therapy areas including advancement of platforms, new drug modalities & new medicinal chemistry strategies

What we offer:

Working with investors on company creation, seed phase strategy or diligence activities

- Developing plans for seed phases
- Interim R&D leadership, advisory board membership & hiring of key staff
- Working with academic founders to bring drug discovery perspective to plans
- Landscape mapping and opportunity triage
- Expert due diligence services for a range of potential transactions

Bringing wide range of expertise & experience

- Project & portfolio strategy & delivery to milestones: target ID to candidate selection
- Neuroscience, oncology, immunology, others
- All aspects of medicinal chemistry including novel platform development
- World-leading expertise in Targeted Protein Degradation & induced proximity
- Use of AI/ML in drug discovery
- Extensive board and investor interactions

Working closely with management teams on strategic plan definition and delivery

- Strategy setting & review
- Refinement of USP & company narrative for investment or deals
- Data review
- Direct portfolio & project oversight and input
 - Target selection
 - Molecule optimisation
 - Proof of concept datasets
 - Milestone data package creation and refinement
- Resource utilization reviews

Track record of delivery

Scientific lead on management team raising \$53M funding round & closing two pharma collaborations (BMS & Merck – total combined value \$74M UF & \$2.3Bn downstream) as CSO at Amphista Therapeutics

Pioneer of Targeted Protein Degradation as Head of Discovery Performance Unit at GSK

Led expansion of AI-powered drug discovery portfolio as SVP Drug Discovery at Benevolent.ai

Multiple projects into development in pharma (Merck, GSK)



E: ian.churcher@janusdrugdiscovery.com
W: <http://www.janusdrugdiscovery.com/>
T: +44 7785 720453

